source
- BrightGene advances obesity drug toward Chinese approval, eyes Western data and partnersBrightGene has submitted its obesity GLP-1 candidate to Chinese regulators after reporting strong Phase 3 results. The company says data from Western trials are expected to be even more robust, wh…
- Sandoz launches direct-to-consumer platform with growth-hormone biosimilar OmnitropeSandoz announced a direct-to-consumer platform, initially offering Omnitrope, a biosimilar growth hormone for growth disorders. The approach follows a trend among brand-name manufacturers to lower…